{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:39:19Z","timestamp":1792013959006,"version":"4.4.0"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["DBT \/2021-22\/IISER-TVM\/1749"],"award-info":[{"award-number":["DBT \/2021-22\/IISER-TVM\/1749"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020512","name":"Indian Institute of Science Education and Research Thiruvananthapuram","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020512","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","award":["SRG\/2021\/000981"],"award-info":[{"award-number":["SRG\/2021\/000981"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.bbrc.2025.153175","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T07:37:22Z","timestamp":1766475442000},"page":"153175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Comparative In silico evaluation of c-Abl inhibitors for Parkinson's disease therapy"],"prefix":"10.1016","volume":"797","author":[{"given":"Devu B.","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6967-8210","authenticated-orcid":false,"given":"Santhosh Kumar","family":"Subramanya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4462-5550","authenticated-orcid":false,"given":"Poonam","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2025.153175_bib1","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","article-title":"Parkinson's disease: clinical features and diagnosis","volume":"79","author":"Jankovic","year":"2008","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"10.1016\/j.bbrc.2025.153175_bib2","doi-asserted-by":"crossref","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.bbrc.2025.153175_bib3","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/s41582-024-01034-x","article-title":"Parkinson disease therapy: current strategies and future research priorities","volume":"20","author":"Stocchi","year":"2024","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.bbrc.2025.153175_bib4","article-title":"The cell biology of Parkinson's disease","volume":"220","author":"Panicker","year":"2021","journal-title":"JCB (J. Cell Biol.)"},{"key":"10.1016\/j.bbrc.2025.153175_bib5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1365-2990.2008.00952.x","article-title":"Review: familial Parkinson's disease \u2013 genetics, clinical phenotype and neuropathology in relation to the common sporadic form of the disease","volume":"34","author":"Schiesling","year":"2008","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.bbrc.2025.153175_bib6","series-title":"Parkinson's Disease: Pathogenesis and Clinical Aspects","article-title":"Parkinson's disease: etiology, neuropathology, and pathogenesis","author":"Kouli","year":"2018"},{"key":"10.1016\/j.bbrc.2025.153175_bib7","doi-asserted-by":"crossref","first-page":"770","DOI":"10.3390\/pharmaceutics15030770","article-title":"Current treatments and new, tentative therapies for parkinson's disease","volume":"15","author":"Pardo-Moreno","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bbrc.2025.153175_bib8","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1001\/jamaneurol.2023.2679","article-title":"IPX203 vs immediate-release carbidopa-levodopa for the treatment of motor fluctuations in parkinson disease: the RISE-PD randomized clinical trial","volume":"80","author":"Hauser","year":"2023","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.bbrc.2025.153175_bib9","doi-asserted-by":"crossref","DOI":"10.1128\/MCB.01454-13","article-title":"The capable ABL: what is its biological function?","author":"Wang","year":"2014","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.bbrc.2025.153175_bib10","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1523\/JNEUROSCI.1833-10.2011","article-title":"Novel regulation of parkin function through c-Abl-Mediated tyrosine phosphorylation: implications for parkinson's disease","volume":"31","author":"Imam","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbrc.2025.153175_bib11","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1172\/JCI85456","article-title":"Activation of tyrosine kinase c-Abl contributes to \u03b1-synuclein\u2013induced neurodegeneration","volume":"126","author":"Brahmachari","year":"2016","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.bbrc.2025.153175_bib12","doi-asserted-by":"crossref","first-page":"16691","DOI":"10.1073\/pnas.1006083107","article-title":"Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function","volume":"107","author":"Ko","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbrc.2025.153175_bib13","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s10072-016-2808-2","article-title":"The c-Abl inhibitor in parkinson disease","volume":"38","author":"Zhou","year":"2017","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.bbrc.2025.153175_bib14","doi-asserted-by":"crossref","first-page":"116251","DOI":"10.1016\/j.ejmech.2024.116251","article-title":"Nur77 increases mitophagy and decreases aggregation of \u03b1-synuclein by modulating the p-c-Abl\/p-PHB2 Y121 in \u03b1-synuclein PFF SH-SY5Y cells and mice","volume":"268","author":"Yin","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bbrc.2025.153175_bib15","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3233\/JAD-2009-1062","article-title":"Altered subcellular distribution of c-Abl in alzheimer's disease","volume":"17","author":"Jing","year":"2009","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.bbrc.2025.153175_bib16","doi-asserted-by":"crossref","first-page":"721","DOI":"10.3233\/JAD-2010-1271","article-title":"Tau phosphorylated at tyrosine 394 is found in alzheimer's disease tangles and can be a product of the abl-related kinase","volume":"19","author":"Tremblay","year":"2010","journal-title":"Arg. Journal of Alzheimer\u2019s Disease"},{"key":"10.1016\/j.bbrc.2025.153175_bib17","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1093\/hmg\/ddt674","article-title":"c-Abl phosphorylates \u03b1-synuclein and regulates its degradation: implication for \u03b1-synuclein clearance and contribution to the pathogenesis of Parkinson's disease","volume":"23","author":"Mahul-Mellier","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbrc.2025.153175_bib18","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1093\/hmg\/ddt192","article-title":"Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of \u03b1-synuclein in Parkinson's disease models","volume":"22","author":"Hebron","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbrc.2025.153175_bib19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13024-020-00364-w","article-title":"\u03b1-Synucleinopathy associated c-Abl activation causes p53-dependent autophagy impairment","volume":"15","author":"Karim","year":"2020","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.bbrc.2025.153175_bib20","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1093\/hmg\/ddy143","article-title":"The c-Abl inhibitor, radotinib HCl, is neuroprotective in a preclinical Parkinson's disease mouse model","volume":"27","author":"Lee","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbrc.2025.153175_bib21","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1021\/acsmedchemlett.9b00612","article-title":"Accelerated discovery of novel ponatinib analogs with improved properties for the treatment of parkinson's disease","volume":"11","author":"Kaiser","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bbrc.2025.153175_bib22","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abp9352","article-title":"The c-Abl inhibitor IkT-148009 suppresses neurodegeneration in mouse models of heritable and sporadic Parkinson's disease","volume":"15","author":"Karuppagounder","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbrc.2025.153175_bib23","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ibneur.2022.10.006","article-title":"The c-Abl\/p73 pathway induces neurodegeneration in a Parkinson's disease model","volume":"13","author":"Mar\u00edn","year":"2022","journal-title":"IBRO Neurosci Rep"},{"key":"10.1016\/j.bbrc.2025.153175_bib24","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.1038\/srep04874","article-title":"The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease","volume":"4","author":"Karuppagounder","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrc.2025.153175_bib25","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1046\/j.1365-2141.2002.03881.x","article-title":"Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid","volume":"119","author":"Takayama","year":"2002","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bbrc.2025.153175_bib26","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1182\/blood-2002-10-3059","article-title":"The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr\/Abl-induced leukemia","volume":"101","author":"Wolff","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2025.153175_bib27","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1001\/jamaneurol.2020.4725","article-title":"Efficacy of nilotinib in patients with moderately advanced parkinson disease: a randomized clinical trial","volume":"78","author":"Simuni","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.bbrc.2025.153175_bib28","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1182\/blood-2018-10-881557","article-title":"Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib","volume":"133","author":"Latifi","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2025.153175_bib29","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1182\/blood.V124.21.1783.1783","article-title":"Comparative TKI profiling analyses to explore potential mechanisms of ponatinib-associated arterial thrombotic events","volume":"124","author":"Rivera","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2025.153175_bib30","first-page":"3127","article-title":"The pyrido[2,3-d]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells","volume":"60","author":"Dorsey","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2025.153175_bib31","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0301-472X(00)00243-5","article-title":"Discovery of a novel abl tyrosine kinase inhibitor that selectively induces apoptosis of bcr-abl-positive leukemic cells","volume":"28","author":"Dorsey","year":"2000","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.bbrc.2025.153175_bib32","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ebiom.2019.10.036","article-title":"Small molecule modulator of aggrephagy regulates neuroinflammation to curb pathogenesis of neurodegeneration","volume":"50","author":"Sn","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bbrc.2025.153175_bib33","author":"Subramanya"},{"key":"10.1016\/j.bbrc.2025.153175_bib34","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.3390\/ph15121546","article-title":"FDA-approved kinase inhibitors in preclinical and clinical trials for neurological disorders","volume":"15","author":"Lui","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bbrc.2025.153175_bib35","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/BF00124499","article-title":"Distributed automated docking of flexible ligands to proteins: parallel applications of AutoDock 2.4","volume":"10","author":"Morris","year":"1996","journal-title":"J Computer-Aided Mol Des"},{"key":"10.1016\/j.bbrc.2025.153175_bib36","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1080\/07391102.2013.770373","article-title":"Relationship between a point mutation S97C in CK1\u03b4 protein and its affect on ATP-Binding affinity","volume":"32","author":"Kumar","year":"2014","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.bbrc.2025.153175_bib37","doi-asserted-by":"crossref","first-page":"174234","DOI":"10.1016\/j.ejphar.2021.174234","article-title":"Amelioration of cognitive deficit in zebrafish by an undescribed anthraquinone from Juglans regia L.: an in-silico, in-vitro and in-vivo approach","volume":"906","author":"Devidas","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbrc.2025.153175_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2022.154204","article-title":"Kutkin, iridoid glycosides enriched fraction of Picrorrhiza kurroa promotes insulin sensitivity and enhances glucose uptake by activating PI3K\/Akt signaling in 3T3-L1 adipocytes","volume":"103","author":"Sinha","year":"2022","journal-title":"Phytomedicine"},{"key":"10.1016\/j.bbrc.2025.153175_bib39","doi-asserted-by":"crossref","first-page":"121668","DOI":"10.1016\/j.lfs.2023.121668","article-title":"Phloretin and phlorizin mitigates inflammatory stress and alleviate adipose and hepatic insulin resistance by abrogating PPAR\u03b3 S273-Cdk5 interaction in type 2 diabetic mice","volume":"322","author":"Kumar","year":"2023","journal-title":"Life Sci."},{"key":"10.1016\/j.bbrc.2025.153175_bib40","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijbiomac.2022.03.021","article-title":"Mechanistic behavior and subtle key events during DNA clamp opening and closing in T4 bacteriophage","volume":"208","author":"Bhardwaj","year":"2022","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bbrc.2025.153175_bib41","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1002\/jcb.25555","article-title":"Mutational analysis on membrane associated transporter protein (MATP) and their structural consequences in oculocutaeous albinism type 4 (OCA4)-A molecular dynamics approach","volume":"117","author":"Kamaraj","year":"2016","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.bbrc.2025.153175_bib42","doi-asserted-by":"crossref","first-page":"5587","DOI":"10.1007\/s00894-013-2044-0","article-title":"In-silico screening of cancer associated mutation on PLK1 protein and its structural consequences","volume":"19","author":"Kamaraj","year":"2013","journal-title":"J. Mol. Model."},{"key":"10.1016\/j.bbrc.2025.153175_bib43","doi-asserted-by":"crossref","first-page":"121162","DOI":"10.1016\/j.carbpol.2023.121162","article-title":"Dispersion-corrected DFT calculations and umbrella sampling simulations to investigate stability of Chrysin-cyclodextrin inclusion complexes","volume":"319","author":"Kumar","year":"2023","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.bbrc.2025.153175_bib44","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1080\/07391102.2013.770373","article-title":"Relationship between a point mutation S97C in CK1\u03b4 protein and its affect on ATP-Binding affinity","volume":"32","author":"Kumar","year":"2014","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.bbrc.2025.153175_bib46","article-title":"Review on the use of molecular docking as the first line tool in drug discovery and development","volume":"84","author":"Sahoo","year":"2022","journal-title":"IJPS"},{"key":"10.1016\/j.bbrc.2025.153175_bib47","doi-asserted-by":"crossref","first-page":"W345","DOI":"10.1093\/nar\/gkz424","article-title":"PrankWeb: a web server for ligand binding site prediction and visualization","volume":"47","author":"Jendele","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbrc.2025.153175_bib48","series-title":"Free Download: BIOVIA Discovery Studio Visualizer. Dassault Syst\u00e8mes","author":"Syst\u00e8mes","year":"2020"},{"key":"10.1016\/j.bbrc.2025.153175_bib49","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","article-title":"GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers","volume":"1\u20132","author":"Abraham","year":"2015","journal-title":"SoftwareX"},{"key":"10.1016\/j.bbrc.2025.153175_bib50","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF Chimera--a visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bbrc.2025.153175_bib51","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1021\/acs.jcim.3c01053","article-title":"SwissParam 2023: a modern web-based tool for efficient small molecule parametrization","volume":"63","author":"Bugnon","year":"2023","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bbrc.2025.153175_bib52","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/s13205-021-03051-9","article-title":"Molecular modeling piloted analysis for semicarbazone derivative of curcumin as a potent Abl-kinase inhibitor targeting colon cancer","volume":"11","author":"Rodrigues","year":"2021","journal-title":"3 Biotech"},{"key":"10.1016\/j.bbrc.2025.153175_bib53","doi-asserted-by":"crossref","first-page":"12974","DOI":"10.1038\/srep12974","article-title":"Design of substrate-based BCR-ABL kinase inhibitors using the cyclotide scaffold","volume":"5","author":"Huang","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrc.2025.153175_bib54","doi-asserted-by":"crossref","first-page":"100418","DOI":"10.1016\/j.rechem.2022.100418","article-title":"Molecular dynamic simulation, free binding energy calculation of Thiazolo-[2,3-b]quinazolinone derivatives against EGFR-TKD and their anticancer activity","volume":"4","author":"Ahmad Mir","year":"2022","journal-title":"Results Chem."},{"key":"10.1016\/j.bbrc.2025.153175_bib55","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.bbrc.2016.06.117","article-title":"Structural and biochemical studies of the PDGFRA kinase domain","volume":"477","author":"Liang","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2025.153175_bib56","doi-asserted-by":"crossref","first-page":"W357","DOI":"10.1093\/nar\/gkz382","article-title":"SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules","volume":"47","author":"Daina","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbrc.2025.153175_bib57","doi-asserted-by":"crossref","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrc.2025.153175_bib58","doi-asserted-by":"crossref","DOI":"10.1093\/bioinformatics\/btad577","article-title":"A machine learning-based quantitative model (LogBB_Pred) to predict the blood\u2013brain barrier permeability (logBB value) of drug compounds","volume":"39","author":"Shaker","year":"2023","journal-title":"Bioinformatics"},{"key":"10.1016\/j.bbrc.2025.153175_bib59","doi-asserted-by":"crossref","first-page":"W422","DOI":"10.1093\/nar\/gkae236","article-title":"ADMETlab 3.0: an updated comprehensive online ADMET prediction platform enhanced with broader coverage, improved performance, API functionality and decision support","volume":"52","author":"Fu","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbrc.2025.153175_bib60","doi-asserted-by":"crossref","first-page":"W469","DOI":"10.1093\/nar\/gkae254","article-title":"Deep-PK: deep learning for small molecule pharmacokinetic and toxicity prediction","volume":"52","author":"Myung","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbrc.2025.153175_bib61","doi-asserted-by":"crossref","first-page":"W513","DOI":"10.1093\/nar\/gkae303","article-title":"ProTox 3.0: a webserver for the prediction of toxicity of chemicals","volume":"52","author":"Banerjee","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbrc.2025.153175_bib62","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","article-title":"Lead- and drug-like compounds: the rule-of-five revolution","volume":"1","author":"Lipinski","year":"2004","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.bbrc.2025.153175_bib63","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"23","author":"Lipinski","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bbrc.2025.153175_bib64","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1021\/cn100007x","article-title":"Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes","volume":"1","author":"Wager","year":"2010","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.bbrc.2025.153175_bib65","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1021\/cn100008c","article-title":"Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties","volume":"1","author":"Wager","year":"2010","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.bbrc.2025.153175_bib66","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbrc.2025.153175_bib67","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","article-title":"Clinical pharmacokinetics of imatinib","volume":"44","author":"Peng","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.bbrc.2025.153175_bib68","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/jcph.1312","article-title":"Clinical pharmacokinetic and pharmacodynamic overview of nilotinib, a selective tyrosine kinase inhibitor","volume":"58","author":"Tian","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.bbrc.2025.153175_bib69","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.470","article-title":"Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease","volume":"7","author":"Pagan","year":"2019","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.bbrc.2025.153175_bib70","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/mds.28858","article-title":"Parkinson's disease modification through Abl kinase inhibition: an opportunity","volume":"37","author":"Werner","year":"2022","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bbrc.2025.153175_bib71","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1186\/s12967-025-06354-0","article-title":"Recent advances in targeting LRRK2 for Parkinson's disease treatment","volume":"23","author":"Karami","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bbrc.2025.153175_bib72","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/acn3.51776","article-title":"LRRK2 and Parkinson's disease: from genetics to targeted therapy","volume":"10","author":"Sosero","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.bbrc.2025.153175_bib73","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s40478-019-0836-x","article-title":"Alzheimer's disease tau is a prominent pathology in LRRK2 Parkinson's disease","volume":"7","author":"Henderson","year":"2019","journal-title":"acta neuropathol commun"},{"key":"10.1016\/j.bbrc.2025.153175_bib74","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK-25-473082","article-title":"Which is the best tyrosine kinase inhibitor for newly diagnosed chronic myelogenous leukemia?","volume":"45","author":"Shanmuganathan","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.bbrc.2025.153175_bib75","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1107\/S0907444906047287","article-title":"Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia","volume":"63","author":"Cowan-Jacob","year":"2006","journal-title":"Acta Crystallogr. D"},{"key":"10.1016\/j.bbrc.2025.153175_bib76","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1182\/blood-2006-11-057521","article-title":"Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells","volume":"109","author":"J\u00f8rgensen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2025.153175_bib77","first-page":"4244","article-title":"Characterization of potent inhibitors of the bcr-abl and the c-Kit receptor tyrosine Kinases1","volume":"62","author":"Wisniewski","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2025.153175_bib78","first-page":"1","volume":"vol. 77","author":"Zhou","year":"2011"},{"key":"10.1016\/j.bbrc.2025.153175_bib79","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1111\/j.1471-4159.2007.04808.x","article-title":"Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (gleevec) across the mouse blood-brain barrier","volume":"102","author":"Bihorel","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbrc.2025.153175_bib80","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1021\/acs.molpharmaceut.7b00257","article-title":"Brain accumulation of ponatinib and its active metabolite, N-Desmethyl ponatinib, is limited by P-Glycoprotein (P-GP\/ABCB1) and breast cancer resistance protein (BCRP\/ABCG2)","volume":"14","author":"Kort","year":"2017","journal-title":"Mol. Pharm."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X25018911?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X25018911?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:15:30Z","timestamp":1786479330000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X25018911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":79,"alternative-id":["S0006291X25018911"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2025.153175","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative In silico evaluation of c-Abl inhibitors for Parkinson's disease therapy","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2025.153175","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"153175"}}